NI201200081A - Derivados de la cromenona con actividad anti-tumoral - Google Patents

Derivados de la cromenona con actividad anti-tumoral

Info

Publication number
NI201200081A
NI201200081A NI201200081A NI201200081A NI201200081A NI 201200081 A NI201200081 A NI 201200081A NI 201200081 A NI201200081 A NI 201200081A NI 201200081 A NI201200081 A NI 201200081A NI 201200081 A NI201200081 A NI 201200081A
Authority
NI
Nicaragua
Prior art keywords
chromenone
derivatives
tumor activity
preparation
drug
Prior art date
Application number
NI201200081A
Other languages
English (en)
Spanish (es)
Inventor
Christophe Barlaam Bernard
Ple Patrick
Louis Degorce Sebastien
Marie Paul Lambert - Van Der Brempt Christine
Robert Morgentin Remy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201200081A publication Critical patent/NI201200081A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NI201200081A 2009-10-27 2012-04-27 Derivados de la cromenona con actividad anti-tumoral NI201200081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
NI201200081A true NI201200081A (es) 2012-11-07

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200081A NI201200081A (es) 2009-10-27 2012-04-27 Derivados de la cromenona con actividad anti-tumoral

Country Status (41)

Country Link
US (5) US8399460B2 (enExample)
EP (1) EP2493870B1 (enExample)
JP (2) JP5657010B2 (enExample)
KR (1) KR101738195B1 (enExample)
CN (2) CN102712615B (enExample)
AR (1) AR078786A1 (enExample)
AU (1) AU2010311107B9 (enExample)
BR (1) BR112012010124B8 (enExample)
CA (1) CA2776994C (enExample)
CL (1) CL2012001056A1 (enExample)
CO (1) CO6541528A2 (enExample)
CR (1) CR20120217A (enExample)
CU (1) CU20120069A7 (enExample)
CY (1) CY1116143T1 (enExample)
DK (1) DK2493870T3 (enExample)
DO (1) DOP2012000124A (enExample)
EA (1) EA020523B9 (enExample)
EC (1) ECSP12011838A (enExample)
ES (1) ES2530943T3 (enExample)
GT (1) GT201200126A (enExample)
HN (1) HN2012000889A (enExample)
HR (1) HRP20150146T1 (enExample)
IL (1) IL219191A0 (enExample)
IN (1) IN2012DN03328A (enExample)
ME (1) ME02050B (enExample)
MX (1) MX2012005027A (enExample)
MY (1) MY179833A (enExample)
NI (1) NI201200081A (enExample)
NZ (1) NZ599457A (enExample)
PE (1) PE20130149A1 (enExample)
PH (1) PH12012500804A1 (enExample)
PL (1) PL2493870T3 (enExample)
PT (1) PT2493870E (enExample)
RS (1) RS53813B1 (enExample)
SA (1) SA110310808B1 (enExample)
SI (1) SI2493870T1 (enExample)
SM (1) SMT201500036B (enExample)
TW (1) TWI483939B (enExample)
UA (1) UA107474C2 (enExample)
UY (1) UY32978A (enExample)
WO (1) WO2011051704A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
JP6546098B2 (ja) * 2013-03-04 2019-07-17 アストラゼネカ アクチボラグ 組み合わせ処置
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
SG11201609527PA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
AU2015274635B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
JP6346964B2 (ja) 2014-06-13 2018-06-20 ギリアード サイエンシーズ, インコーポレイテッド ホスファチジルイノシトール3−キナーゼ阻害剤
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6912460B2 (ja) * 2015-10-09 2021-08-04 ヤンセン ファーマシューティカ エヌ.ベー. PI3Kβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
KR20240016938A (ko) * 2021-02-01 2024-02-06 지오드 테라퓨틱스 인크. 포스포이노시티드 3 키나아제 베타 억제제 및 그 조성물 및 방법
KR20240004744A (ko) * 2021-05-03 2024-01-11 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
EP4333984A1 (en) * 2021-05-03 2024-03-13 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
JP7702057B2 (ja) * 2021-05-27 2025-07-03 ペトラ・ファーマ・コーポレイション がんの治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
WO2023060262A1 (en) * 2021-10-07 2023-04-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
CN118742545A (zh) * 2021-12-08 2024-10-01 南京征祥医药有限公司 作为PI3Kα抑制剂的稠合杂环化合物
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
EP4602031A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. Methods for treating cancer
WO2025026442A1 (zh) * 2023-08-02 2025-02-06 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
RU2118321C1 (ru) 1988-12-21 1998-08-27 Дзе Апджон Компани Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты
CA2081577A1 (en) 1990-06-20 1991-12-21 Ronald B. Gammill Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
CN1891693A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
CN101506211B (zh) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
HRP20150146T1 (hr) 2015-05-22
DK2493870T3 (en) 2015-02-23
IN2012DN03328A (enExample) 2015-10-23
CR20120217A (es) 2012-06-28
UY32978A (es) 2011-05-31
US8399460B2 (en) 2013-03-19
KR20120098724A (ko) 2012-09-05
PH12012500804A1 (en) 2022-10-03
US9029374B2 (en) 2015-05-12
HN2012000889A (es) 2015-08-03
US20160060240A1 (en) 2016-03-03
ES2530943T3 (es) 2015-03-09
EA201200618A1 (ru) 2012-12-28
JP5872016B2 (ja) 2016-03-01
CN104447657B (zh) 2016-08-17
US20110098271A1 (en) 2011-04-28
HK1206335A1 (zh) 2016-01-08
SI2493870T1 (sl) 2015-03-31
IL219191A0 (en) 2012-06-28
EP2493870B1 (en) 2014-12-17
PT2493870E (pt) 2015-02-18
SA110310808B1 (ar) 2013-11-24
EP2493870A1 (en) 2012-09-05
BR112012010124A2 (pt) 2016-06-07
CN102712615B (zh) 2014-12-17
NZ599457A (en) 2014-04-30
UA107474C2 (uk) 2015-01-12
US20140194419A1 (en) 2014-07-10
AU2010311107A1 (en) 2012-05-03
CL2012001056A1 (es) 2012-10-05
JP2015078202A (ja) 2015-04-23
CN104447657A (zh) 2015-03-25
DOP2012000124A (es) 2012-07-15
TW201121960A (en) 2011-07-01
ME02050B (me) 2015-05-20
ECSP12011838A (es) 2012-06-29
JP5657010B2 (ja) 2015-01-21
JP2013508449A (ja) 2013-03-07
CN102712615A (zh) 2012-10-03
US8673906B2 (en) 2014-03-18
BR112012010124B1 (pt) 2021-02-17
GT201200126A (es) 2014-03-03
EA020523B1 (ru) 2014-11-28
MY179833A (en) 2020-11-17
PE20130149A1 (es) 2013-03-10
WO2011051704A1 (en) 2011-05-05
CA2776994A1 (en) 2011-05-05
US20160272607A1 (en) 2016-09-22
HK1174027A1 (en) 2013-05-31
KR101738195B1 (ko) 2017-05-19
US20130158026A1 (en) 2013-06-20
CU20120069A7 (es) 2012-10-15
CO6541528A2 (es) 2012-10-16
CA2776994C (en) 2017-10-31
MX2012005027A (es) 2012-09-07
SMT201500036B (it) 2015-05-05
AU2010311107B9 (en) 2014-06-19
BR112012010124B8 (pt) 2021-05-25
RS53813B1 (sr) 2015-06-30
PL2493870T3 (pl) 2015-04-30
AR078786A1 (es) 2011-11-30
AU2010311107B2 (en) 2014-03-27
EA020523B9 (ru) 2015-01-30
CY1116143T1 (el) 2017-02-08
US9718800B2 (en) 2017-08-01
TWI483939B (zh) 2015-05-11

Similar Documents

Publication Publication Date Title
NI201200081A (es) Derivados de la cromenona con actividad anti-tumoral
UY30183A1 (es) Derivados de quinolina
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY31430A1 (es) Derivados de piridina y pirazina -83
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
NI201500013A (es) Tratamiento de enfermedades inmuno - relacionadas e inflamatorias.
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
NI201300081A (es) Uso de 3 - ( 5 - amino - 2 - metil - 4 - oxoquinazolin - 3(4h) - il) piperidin - 2 - 6 -diona en el tratamiento de enfermedades relacionadas con el sistema inmunitario e inflamatorias.
MY169986A (en) Benzimidazole-proline derivatives
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
UY31141A1 (es) Compuestos de piperidina y sus usos
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции